178 related articles for article (PubMed ID: 24245788)
1. The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer.
Gidwani B; Vyas A
Artif Cells Nanomed Biotechnol; 2015; 43(4):291-7. PubMed ID: 24245788
[TBL] [Abstract][Full Text] [Related]
2. Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.
Rhoda K; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Pillay V
Expert Opin Drug Deliv; 2015 Apr; 12(4):613-34. PubMed ID: 25300775
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology applied to overcome tumor drug resistance.
Gao Z; Zhang L; Sun Y
J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology in ovarian cancer: Diagnosis and treatment.
Barani M; Bilal M; Sabir F; Rahdar A; Kyzas GZ
Life Sci; 2021 Feb; 266():118914. PubMed ID: 33340527
[TBL] [Abstract][Full Text] [Related]
5. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
6. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
Talekar M; Kendall J; Denny W; Garg S
Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells.
Taratula O; Dani RK; Schumann C; Xu H; Wang A; Song H; Dhagat P; Taratula O
Int J Pharm; 2013 Dec; 458(1):169-80. PubMed ID: 24091153
[TBL] [Abstract][Full Text] [Related]
8. Has nanotechnology led to improved therapeutic outcomes?
Bosselmann S; Williams RO
Drug Dev Ind Pharm; 2012 Feb; 38(2):158-70. PubMed ID: 22191583
[TBL] [Abstract][Full Text] [Related]
9. Bridging cancer biology and the patients' needs with nanotechnology-based approaches.
Fonseca NA; Gregório AC; Valério-Fernandes A; Simões S; Moreira JN
Cancer Treat Rev; 2014 Jun; 40(5):626-35. PubMed ID: 24613464
[TBL] [Abstract][Full Text] [Related]
10. Advances and challenges of nanotechnology-based drug delivery systems.
Jiang W; Kim BY; Rutka JT; Chan WC
Expert Opin Drug Deliv; 2007 Nov; 4(6):621-33. PubMed ID: 17970665
[TBL] [Abstract][Full Text] [Related]
11. Colloidal systems for tumor targeting.
Storm G; Crommelin DJ
Hybridoma; 1997 Feb; 16(1):119-25. PubMed ID: 9085138
[TBL] [Abstract][Full Text] [Related]
12. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
13. [New approaches to the selective transport of antineoplastic agents: cell physiology and nanotechnology].
Severin ES; Posypanova GA
Fiziol Zh (1994); 2011; 57(5):73-4. PubMed ID: 22276313
[No Abstract] [Full Text] [Related]
14. Nanocarriers for the targeted treatment of ovarian cancers.
Tomasina J; Lheureux S; Gauduchon P; Rault S; Malzert-Fréon A
Biomaterials; 2013 Jan; 34(4):1073-101. PubMed ID: 23174141
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology-based drug delivery for cancer.
Jain KK
Technol Cancer Res Treat; 2005 Aug; 4(4):407-16. PubMed ID: 16029059
[TBL] [Abstract][Full Text] [Related]
16. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
Chen JN; Shen Q; Li SS
Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system.
Bamrungsap S; Zhao Z; Chen T; Wang L; Li C; Fu T; Tan W
Nanomedicine (Lond); 2012 Aug; 7(8):1253-71. PubMed ID: 22931450
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle and targeted systems for cancer therapy.
Brannon-Peppas L; Blanchette JO
Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.
Corradetti B; Pisano S; Conlan RS; Ferrari M
J Pharmacol Exp Ther; 2019 Sep; 370(3):636-646. PubMed ID: 30737357
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.
Leung AW; Kalra J; Santos ND; Bally MB; Anglesio MS
Nanomedicine (Lond); 2014 Mar; 9(3):501-22. PubMed ID: 24746193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
